22:33 , May 2, 2019 |  BC Innovations  |  Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
14:43 , Apr 26, 2019 |  BC Week In Review  |  Company News

Orgenesis licenses cancer vaccine from Columbia

Orgenesis gained an exclusive license to a cellular vaccination product platform from Columbia University. Orgenesis Inc. (OTCQX:ORGS) will fund research at the university to develop the technology to treat pancreatic, hepatic and cholangiocarcinoma cancers. The...
18:35 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Sotio's DCVAC/OvCa improves survival in Phase II for recurrent ovarian cancer

Sotio reported March 19 that DCVAC/OvCa as second-line treatment decreased the risk of death by 62% in the Phase II SOV02 trial to treat recurrent, platinum-sensitive epithelial ovarian cancer. DCVAC/OvCa is an active cellular immunotherapy...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
22:22 , Mar 18, 2019 |  BC Extra  |  Company News

Astellas adds more drug delivery tech via NapaJen deal

Astellas has completed a second deal for a drug delivery technology, this time with NapaJen, that stands to add a new modality to its pipeline. Astellas Pharma Inc. (Tokyo:4503) will use oligonucleotide delivery technology from...
19:14 , Mar 14, 2019 |  BC Innovations  |  Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

Silverback’s antibody-based conjugates stimulate innate and adaptive immunity by turning myeloid cells against tumors, while overcoming resistance to checkpoint inhibitors and other T cell-targeting immunotherapies. “When you are able to appropriately and potently activate myeloid...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
19:20 , Feb 22, 2019 |  BC Week In Review  |  Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is...
23:33 , Feb 21, 2019 |  BC Extra  |  Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...